The Latest Breaking News from AXGN

AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam

AxoGen (NASDAQ:AXGN) President and CEO Michael Dale said the company’s growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified. Speaking during a company event, Dale said he w

MarketBeat · May 14

Axogen Smashes 52-Week High On FDA Nod For Breakthrough Nerve Repair Treatment

The U.S. Food and Drug Administration (FDA) on Wednesday approved Axogen Inc.’s (NASDAQ:AXGN) Biologics License Application for Avance, an acellular nerve scaffold for adult and pediatric patients aged 1 month or older with sensory, mixed, and motor peripheral nerve discontinuities.

Benzinga · Dec 4, 2025

FDA Pushes Back Axogen Avance Nerve Graft Decision By 3 Months

The U.S. Food and Drug Administration (FDA) on Monday extended the Prescription Drug User Fee Act (PDUFA) goal date for Axogen Inc.’s (NASDAQ:AXGN) Biologics License Application (BLA) for Avance Nerve Graft by three months to December 5.

Benzinga · Aug 25, 2025